BRPI0418074A - derivado de amida e medicamento - Google Patents

derivado de amida e medicamento

Info

Publication number
BRPI0418074A
BRPI0418074A BRPI0418074-7A BRPI0418074A BRPI0418074A BR PI0418074 A BRPI0418074 A BR PI0418074A BR PI0418074 A BRPI0418074 A BR PI0418074A BR PI0418074 A BRPI0418074 A BR PI0418074A
Authority
BR
Brazil
Prior art keywords
amide derivative
present
tyrosine kinase
bcr
medicine
Prior art date
Application number
BRPI0418074-7A
Other languages
English (en)
Inventor
Tetsuo Asaki
Yukiteru Sugiyama
Jun Segawa
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of BRPI0418074A publication Critical patent/BRPI0418074A/pt
Publication of BRPI0418074B1 publication Critical patent/BRPI0418074B1/pt
Publication of BRPI0418074B8 publication Critical patent/BRPI0418074B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADO DE AMIDA E MEDICAMENTO". A presente invenção refere-se a um derivado de amida tendo excelente atividade inibitória da tirosina cinase BCR-ABL, ou um sal do mesmo. A presente invenção fornece um derivado de amida representa pela fórmula geral (1) a seguir: ¢Composto químico 23! (onde R¬ 1¬ representa -CH~ 2~-R¬ 11¬ etc.; R¬ 2¬ representa alquila, halogênio, haloalquila, etc.; R¬ 3¬ representa hidrogênio, etc.; Het1 representa um grupo da fórmula ¢6! acima, etc.; e Het2 representa pirimidinila, etc.) ou um sal farmaceuticamente aceitável do mesmo, e uma composição farmacêutica compreendendo o mesmo como um ingrediente ativo. O composto da presente invenção é útil como inibidor da tirosina cinase BCR-ABL.
BRPI0418074A 2003-12-25 2004-12-27 derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos BRPI0418074B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003431398 2003-12-25
JP2003-431398 2003-12-25
PCT/JP2004/019553 WO2005063709A1 (ja) 2003-12-25 2004-12-27 アミド誘導体及び医薬

Publications (3)

Publication Number Publication Date
BRPI0418074A true BRPI0418074A (pt) 2007-04-17
BRPI0418074B1 BRPI0418074B1 (pt) 2019-06-18
BRPI0418074B8 BRPI0418074B8 (pt) 2021-05-25

Family

ID=34736430

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418074A BRPI0418074B8 (pt) 2003-12-25 2004-12-27 derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos

Country Status (19)

Country Link
US (1) US7728131B2 (pt)
EP (2) EP3299358A1 (pt)
JP (3) JPWO2005063709A1 (pt)
KR (1) KR100848067B1 (pt)
CN (2) CN101456841B (pt)
AU (1) AU2004309248B2 (pt)
BR (1) BRPI0418074B8 (pt)
CA (1) CA2551529C (pt)
CY (1) CY1120169T1 (pt)
DK (1) DK1702917T3 (pt)
ES (1) ES2651615T3 (pt)
HU (1) HUE034712T2 (pt)
LT (1) LT1702917T (pt)
MX (1) MXPA06007237A (pt)
PL (1) PL1702917T3 (pt)
PT (1) PT1702917T (pt)
RU (1) RU2410375C9 (pt)
SI (1) SI1702917T1 (pt)
WO (1) WO2005063709A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP2007297306A (ja) * 2006-04-28 2007-11-15 Kaneka Corp 光学活性３−（１−ピロリジニル）ピロリジンの製造法
US8093259B2 (en) 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CN103342701B (zh) 2007-02-13 2016-09-21 Ab科学有限公司 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
CN102548987B (zh) * 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
CN104402860A (zh) * 2010-05-19 2015-03-11 江苏豪森药业股份有限公司 甲磺酸伊马替尼中间体的制备方法
CN102477009B (zh) * 2010-11-23 2014-01-01 清华大学深圳研究生院 取代的（s）-苯甲磺酰基吡咯烷-3-氨基衍生物及其制备方法与应用
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
FR2980477B1 (fr) * 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
BR112014026305A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
BR112014026266A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂
CN106187995A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含酰胺键杂环类化合物及其制备方法和应用
EP3313530B1 (en) * 2015-06-26 2022-10-05 Dana Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6994715B2 (ja) * 2017-10-04 2022-02-04 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20220048893A1 (en) * 2019-03-05 2022-02-17 Hongyi & Associates Llc Compounds for Treating Neurodegenerative Diseases and Cancers
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US7494997B2 (en) * 2002-06-28 2009-02-24 Nippon Shinyaku Co., Ltd. Amide derivative
DE60316810T2 (de) * 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US20070191267A1 (en) * 2003-04-28 2007-08-16 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
CA2535242A1 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes

Also Published As

Publication number Publication date
KR100848067B1 (ko) 2008-07-23
DK1702917T3 (da) 2017-11-13
RU2410375C9 (ru) 2017-08-02
US20080293940A1 (en) 2008-11-27
JPWO2005063709A1 (ja) 2007-07-19
CN101456841A (zh) 2009-06-17
HUE034712T2 (hu) 2018-02-28
BRPI0418074B8 (pt) 2021-05-25
PT1702917T (pt) 2017-11-14
RU2410375C2 (ru) 2011-01-27
LT1702917T (lt) 2017-12-11
EP3299358A1 (en) 2018-03-28
WO2005063709A1 (ja) 2005-07-14
US7728131B2 (en) 2010-06-01
BRPI0418074B1 (pt) 2019-06-18
EP1702917A4 (en) 2009-06-03
CY1120169T1 (el) 2018-12-12
MXPA06007237A (es) 2006-08-18
CN100526298C (zh) 2009-08-12
AU2004309248B2 (en) 2009-11-05
JP2012121893A (ja) 2012-06-28
ES2651615T3 (es) 2018-01-29
SI1702917T1 (en) 2018-01-31
CN1898208A (zh) 2007-01-17
CA2551529C (en) 2011-02-01
CA2551529A1 (en) 2005-07-14
EP1702917A1 (en) 2006-09-20
KR20060127901A (ko) 2006-12-13
AU2004309248A1 (en) 2005-07-14
PL1702917T3 (pl) 2018-02-28
RU2006126974A (ru) 2008-01-27
JP2014196291A (ja) 2014-10-16
CN101456841B (zh) 2012-01-25
EP1702917B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
BR0312288A (pt) Derivados de amidas
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EP1566379A4 (en) CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
HUP0203965A2 (en) Indazole compounds and pharmaceutical compositions containing them
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BR0315580A (pt) Derivados de metileno uréia
BR0309558A (pt) Derivados de quinazolina e medicamentos
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
MA27887A1 (fr) Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine
GEP20115240B (en) Indole derivatives, process for their preparation and pharmaceutical compositions containing them
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
DK0911026T3 (da) Creatinderivater for astma
BR0009135A (pt) Derivado de benzamida e medicamento que ocontém
ATE325116T1 (de) Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF